Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Design, Synthesis, Characterisation, and Evaluation of Substituted Quinolin-2-one Derivatives as Possible Anti-lung Cancer Agents

Author(s): Riya Swar, Prachita Gauns Dessai*, Shivalingrao MamleDesai, Sachin Chandavarkar, Soniya Phadte and Bheemanagouda Biradar

Volume 21, Issue 4, 2024

Published on: 26 December, 2023

Article ID: e261223224851 Pages: 12

DOI: 10.2174/0115701638258479231220051227

Price: $65

Abstract

Background: According to 2022, the estimated number of cancer cases in India was found to be 1,461,427. Lung cancers are the leading cause of death among Indian males. Research on cancer has been conducted to develop better treatments that are safe and effective and could be used to diagnose cancer at an early stage. It was found that quinolin-2-one possesses anticancer activity, which led us to synthesize substituted quinolin-2-one derivatives that can provide a longer future to cancer patients and decrease the risk of dying from cancer.

Objective: This study aimed to carry out the design, synthesis, characterisation, and evaluation of novel substituted quinolin-2-one analogues as possible anti-lung cancer agents.

Methods: Compound III a/III b on reaction with acids, sodium acetate and ethylchloroacetate, substituted benzaldehyde, phthalic anhydride, and 2N sodium hydroxide yielded compounds IV a/ IV b, V a/ V b, VI a/ VI b, VI c/ VI d, VI e/ VI f, VII a/ VII b, and VIII a/ VIII b, respectively.

Result: Among all the synthesised derivatives, compound VII a was found to be most potent with a MolDock score of -132.78 as compared to standard drug imatinib (-114.37) and active ligand 4- anilinoquinazoline (-126.71). All the synthesized derivatives showed a good ADME profile, but compound VII a showed the best ADME data among all the synthesised derivatives.

All the synthesised compounds were tested for their in vitro anticancer activity against the Hop-62 (human lung cancer) cell line, out of which compound VII a was found to be most potent, with a percent control growth of -51.7% at a concentration of 80 μg/ml, which was in comparable to the positive control, Adriamycin (-70.5%) and standard imatinib (-84.0%).

Conclusion: Compound VII a showed the highest MolDock score and was most potent against human lung cancer cell line Hop-62.

[1]
Available from: https://www.medicalnewstoday.com/articles/323701#types(Assessed on 4th July 2021).
[2]
Kleihues P, Sobin LH. World health organization classifcation of tumors. Cancer 2000; 88(12): 2887-7.
[3]
Dessai PG, Dessai SP, Dabholkar R, Pednekar P, Naik S, et al. Synthesis, graph theoretical analysis and molecular modelling studies of novel substituted quinoline analogues as promising anti-breast cancer agents. Mol Divers 2022.
[http://dx.doi.org/10.1007/s11030-022-10512-7] [PMID: 35976550]
[4]
Lei S, Zheng R, Zhang S, et al. Breast cancer incidence and mortality in women in China: temporal trends and projections. Cancer Biol Med 2021; 18(3): 900.
[5]
Tripathi KD. Essentials of medical pharmacology. (7th ed.). New Delhi: JP Medical Ltd. 2013; p. 411.
[6]
Available from: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/chemotherapy-side-effects.html
[7]
Available from: https://www.healthline.com/health/chemotherapy
[8]
Available from: https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer-treatment/art-20046192
[9]
Priolkar RNS, Shingade S, Palkar M, Desai SM. Design, synthesis, and characterization of novel linomide analogues and their evaluation for anticancer activity. Curr Drug Discov Technol 2020; 17(2): 203-12.
[http://dx.doi.org/10.2174/1570163815666181008151037] [PMID: 30306874]
[10]
Spears M, Taylor KJ, Munro AF, et al. In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res Treat 2012; 132(2): 463-70.
[http://dx.doi.org/10.1007/s10549-011-1606-z] [PMID: 21638049]
[11]
Zhang Q, Chen Y, Zheng YQ, et al. Synthesis and bioactivity of 4,10-dimethyl-pyridino[2,3-h]quinolin-2(1H)-one-9-carboxylic acid and its esters. Bioorg Med Chem 2003; 11(6): 1031-4.
[http://dx.doi.org/10.1016/S0968-0896(02)00526-6] [PMID: 12614889]
[12]
Ohashi T, Oguro Y, Tanaka T, et al. Discovery of pyrrolo[3,2-c]quinoline-4-one derivatives as novel hedgehog signaling inhibitors. Bioorg Med Chem 2012; 20(18): 5496-506.
[http://dx.doi.org/10.1016/j.bmc.2012.07.039] [PMID: 22910224]
[13]
Afzal O, Kumar S, Haider MR, et al. A review on anticancer potential of bioactive heterocycle quinoline. Eur J Med Chem 2015; 97: 871-910.
[14]
Ogino K, Hobara T, Ishiyama H, et al. Antiulcer mechanism of action of rebamipide, a novel antiulcer compound, on diethyldithiocarbamate-induced antral gastric ulcers in rats. Eur J Pharmacol 1992; 212(1): 9-13.
[http://dx.doi.org/10.1016/0014-2999(92)90065-C] [PMID: 1313372]
[15]
(a) Trinquand C, Romanet J, Nordmann J, Allaire C. Efcacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study. J Fr Ophtalmol 26(2): 131-6. 22.;
(b) De Fruyt J, Deschepper E, Audenaert K, et al. (2012) Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol 2003; 26(5): 603-17.
[http://dx.doi.org/10.1177/0269881111408461]
[16]
Reis Md G, Desai SM, Naik S, Fernandes J, Tari P. Synthesis and evaluation of 2-(4-methoxy-2-oxo-1-phenyl/methyl-1, 2-dihydroquinolin-3-yl)-2-methyl-3-(phenyl/substitutedphenyl-amino) thiazolidin-4-one as antibacterial and anticancer agents. Indian J Chem 2016; 55B: 1254-8.
[17]
Jansen O, Akhmedjanova V, Angenot L, et al. Screening of 14 alkaloids isolated from Haplophyllum A. Juss for their cytotoxic properties. J Ethnopharmacol 2006; 105: 241-5.
[18]
Shi J, Xiao Z, Ihnat MA, et al. Structure-activity relationships studies of the anti-angiogenic activities of linomide. Bioorg Med Chem Lett 2003; 13(6): 1187-9.
[http://dx.doi.org/10.1016/S0960-894X(03)00047-7] [PMID: 12643940]
[19]
Li Q, Woods KW, Wang W, et al. Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors. Bioorg Med Chem Lett 2005; 15(8): 2033-9.
[http://dx.doi.org/10.1016/j.bmcl.2005.02.062] [PMID: 15808463]
[20]
Jochmans D. Novel HIV-1 reverse transcriptase inhibitors. Virus Res 2008; 134(1-2): 171-85.
[21]
Palkar MB, Singhai AS, Ronad PM, et al. Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents. Bioorg Med Chem 2014; 22(10): 2855-66.
[PMID: 24751552]
[22]
Available from: https://www.nature.com/articles/srep42717
[23]
Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017; 7: 42717.
[http://dx.doi.org/10.1038/srep42717] [PMID: 28256516]
[24]
Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006; 1(3): 1112-6.
[PMID: 17406391]
[25]
Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82(13): 1107-12.
[PMID: 2359136]
[26]
The site at which the known 4-anilinoquinazoline inhibitor binds. Available from: https://www.ebi.ac.uk/pdbe/entry/pdb/1m17/bound/AQ4(Assessed on 16th March 2021).
[27]
Functional details of 1m17. Available from: https://pdbj.org/mine/functional_details/1m17 (Assessed on 16th March 2021).

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy